GLP - 1NCT07505134
Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements
A study testing Food advertisements and Tech advertisements in people with GLP - 1, run by Penn State University.
Trial summary
The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- GLP - 1
- What is being tested?
- Food advertisements and Tech advertisements
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults (18+) with overweight or obesity (BMI >25 kg/m2)
- On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
- Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
- Fluent in English
Who cannot join
- Do not have consistent access to a smart phone that can access the study software
- Diagnosed with cognitive or physical disability or epilepsy
- Adults taking a compound GLP-1
About this study
Official title: Exploring the Influence of GLP-1 Medications on External Food Cue Reactivity and Resultant Food Choice and Intake
The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?
Participants will:
- report daily food consumption for a total of 10 days,
- receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days,
- answer several questionnaires,
- and complete two in-person visits to complete a virtual reality food selection task.
- Conditions
- GLP - 1
- Being tested
- Food advertisements, Tech advertisements
- Keywords
- GLP-1, Food choice, Cravings, Food cue reactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Food advertisementsBehavioural
Videos and images of food and beverage advertisements from popular brands and/or restaurants
Tech advertisementsBehavioural
Video and photo advertisements of popular tech tools
| Study group | Role | What they receive |
|---|---|---|
| Food advertisement group | Experimental | Advertisements viewed daily by this group will be food and/or beverage products Receives: Behavioral: Food advertisements |
| Tech advertisement group | Placebo comparator | Individuals in this group will only receive tech-related advertisements daily Receives: Behavioral: Tech advertisements |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean food cue reactivity scores in the afternoon
Average scores of craving levels for each group following afternoon advertisement viewing sessions
Measured: 7-day period of all afternoon survey responses
Mean food cue reactivity scores in the morning
Average scores of craving levels for each group following morning advertisement viewing sessions
Measured: 7-day period of all morning survey responses
Mean food cue reactivity scores in the evening
Average scores of craving levels for each group following evening advertisement viewing sessions
Measured: 7-day period of all evening survey responses
Mean food cue reactivity scores overall
Average scores of craving levels for each group over all viewing sessions
Measured: 7-day period of all survey responses
Energy density of consumed foods
The energy density profile of foods consumed each day
Measured: 7 days
Secondary outcomes (5)
Change from baseline in energy density of foods selected in the virtual buffet
Measured: Baseline and 7 days
Changes in food noise since being on medication questionnaire
Questionnaire assessing various aspects of food noise at present compared to before the medication
Measured: Baseline
Changes in reasons for purchasing foods questionnaire
A questionnaire that assesses how five factors impact purchasing choices, and how the main factors have changed between prior to starting the medication and after.
Measured: Baseline
Individual Food Cue Responsiveness--Trait
Measured: Baseline
Change in brand familiarity, liking, and/or craving
A questionnaire that measures the familiarity, liking, and craving of each brand the participant will be exposed to (baseline) or has been exposed to (after intervention).
Measured: Baseline and 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2026
- Study startSep 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GLP - 1Studies of the same condition, open and under way.
- More trials run by Penn State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Penn State University
- Sponsor type
- University, hospital or other
- Collaborators
- Penn State Health
- Responsible party
- Principal investigator, Travis Masterson, Penn State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07505134
- Sponsor's protocol ID
- STUDY00028881
- Status last verified
- Apr 2026
- First submitted
- 17 Mar 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Influence of GLP-1 Medications on External Food Cue Reactivity and Resultant Food Choice and Intake
- ClinicalTrials.gov ID
- NCT07505134
- Acronym / sponsor ID
- STUDY00028881
- Conditions
- GLP - 1
- Keywords
- GLP-1, Food choice, Cravings, Food cue reactivity
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Penn State UniversityUniversity, hospital or other
- Collaborators
- Penn State Health
- Study start
- Sep 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 1 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?
Participants will:
- report daily food consumption for a total of 10 days,
- receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days,
- answer several questionnaires,
- and complete two in-person visits to complete a virtual reality food selection task.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Food advertisement group | Experimental | Behavioral: Food advertisementsAdvertisements viewed daily by this group will be food and/or beverage products |
| Tech advertisement group | Placebo comparator | Behavioral: Tech advertisementsIndividuals in this group will only receive tech-related advertisements daily |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults (18+) with overweight or obesity (BMI >25 kg/m2)
- On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
- Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
- Fluent in English
Key exclusion criteria (3 listed)
- Do not have consistent access to a smart phone that can access the study software
- Diagnosed with cognitive or physical disability or epilepsy
- Adults taking a compound GLP-1
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Food advertisementsVideos and images of food and beverage advertisements from popular brands and/or restaurants | Behavioural | Food advertisement group |
| Tech advertisementsVideo and photo advertisements of popular tech tools | Behavioural | Tech advertisement group |
Primary outcome
Mean food cue reactivity scores in the afternoon
Time frame: 7-day period of all afternoon survey responses
Average scores of craving levels for each group following afternoon advertisement viewing sessions
Mean food cue reactivity scores in the morning
Time frame: 7-day period of all morning survey responses
Average scores of craving levels for each group following morning advertisement viewing sessions
Mean food cue reactivity scores in the evening
Time frame: 7-day period of all evening survey responses
Average scores of craving levels for each group following evening advertisement viewing sessions
Mean food cue reactivity scores overall
Time frame: 7-day period of all survey responses
Average scores of craving levels for each group over all viewing sessions
Energy density of consumed foods
Time frame: 7 days
The energy density profile of foods consumed each day
5 secondary outcomes
Change from baseline in energy density of foods selected in the virtual buffet
Time frame: Baseline and 7 days
Changes in food noise since being on medication questionnaire
Time frame: Baseline
Changes in reasons for purchasing foods questionnaire
Time frame: Baseline
Individual Food Cue Responsiveness--Trait
Time frame: Baseline
Change in brand familiarity, liking, and/or craving
Time frame: Baseline and 7 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
Related trials for GLP - 1
RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Obesity or Overweight
RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Overweight or Obesity
Not yet recruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
RecruitingPhase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic Arthritis (PsA)
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Food advertisements and Tech advertisements in people with GLP - 1, run by Penn State University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean food cue reactivity scores in the afternoon (time frame: 7-day period of all afternoon survey responses). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.